Opthea's technology is centred on VEGF-C, VEGF-D and VEGFR-3.

VEGF-C and VEGF-D promote blood and lymphatic vessel development. VEGF-C also causes vessels to leak.

OPT-302 blocks the activity of VEGF-C and VEGF-D and is being developed for the treatment of wet AMD, the leading cause of blindness in the Western world.

Wet AMD is characterised by loss of vision in the centre of the visual field and is caused by the abnormal growth and leakage of vessels at the back of the eye. Blocking the signals that lead to this abnormal vessel growth and vascular leakage has the potential to improve patients' vision.